Holen Sie sich die Stockscreener-App
11.71
4.83%
-0.41
Schlusskurs vom Vortag:
$12.12
Offen:
$12.19
24-Stunden-Volumen:
25,486
Relative Volume:
0.15
Marktkapitalisierung:
$397.01M
Einnahmen:
$7,000
Nettoeinkommen (Verlust:
$-34.48M
KGV:
-11.65
EPS:
-1.0054
Netto-Cashflow:
$-22.13M
1W Leistung:
+1.72%
1M Leistung:
+11.13%
6M Leistung:
-16.71%
1J Leistung:
-22.06%
1-Tages-Spanne:
$11.33
$12.48
1-Wochen-Bereich:
$11.33
$13.39
52-Wochen-Spanne:
$9.85
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Firmenname
Benitec Biopharma Inc
Sektor
Branche
Telefon
(510) 780-0819
Adresse
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.59 | 415.17M | 7,000 | -34.48M | -22.13M | -1.0054 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.84 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.46 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.22 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-12 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-05 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-02-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-12-31 | Bestätigt | Maxim Group | Buy |
| 2015-09-16 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Benitec Biopharma Inc Aktie (BNTC) Neueste Nachrichten
Surprises Report: Can Benitec Biopharma Inc maintain its current growth rate2026 Fundamental Recap & Intraday High Probability Alerts - baoquankhu1.vn
(BNTC) Risk Channels and Responsive Allocation - Stock Traders Daily
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for - The Manila Times
Breakfast talk to show OPMD swallowing gains from gene therapy BB-301 - Stock Titan
Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright - Defense World
Cowen Reiterates Buy on Benitec Biopharma (BNTC) March 2026 - Meyka
Market Pulse: Is Benitec Biopharma Inc stock a good dividend stock2026 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn
Benitec BioPharma stock maintains Buy rating on positive trial data - Investing.com
BNTC: HC Wainwright & Co. Reiterates Buy Rating on Benitec Bioph - GuruFocus
Benitec reports interim results from gene therapy trial - Investing.com Nigeria
Benitec Biopharma (BNTC) Reports Encouraging Interim Results fro - GuruFocus
Benitec's BB-301 delivers durable swallowing gains in OPMD - Stock Titan
Benitec Biopharma Stock Pre-Market (+7.1%): Analyst Raises EPS Forecasts - Trefis
Sentiment Recap: What is the Moat Score of Benitec Biopharma IncJuly 2025 Outlook & Stock Timing and Entry Methods - baoquankhu1.vn
New Highs: How liquid is Benitec Biopharma Inc stockJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
HC Wainwright Expects Higher Earnings for Benitec Biopharma - Defense World
HC Wainwright Issues Optimistic Forecast for BNTC Earnings - MarketBeat
Levels Update: Is Benitec Biopharma Inc exposed to political riskTreasury Yields & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Research Analysts Offer Predictions for BNTC Q1 Earnings - Defense World
Analysts Issue Forecasts for BNTC Q1 Earnings - MarketBeat
(BNTC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Benitec Biopharma Inc. (BNTC) - DirectorsTalk Interviews
Benitec BioPharma stock rating maintained on gene therapy data - Investing.com Nigeria
Benitec BioPharma stock rating maintained on gene therapy data By Investing.com - Investing.com Australia
Benitec Biopharma Announces Acceptance of Late- Breaking - GlobeNewswire
Durable BB-301 responses in muscular dystrophy to be detailed at MDA 2026 - Stock Titan
Benitec Biopharma (BNTC) Stock Analysis: Unpacking A 125% Potential Upside - DirectorsTalk Interviews
Liquidity Mapping Around (BNTC) Price Events - Stock Traders Daily
What insider trading reveals about Benitec Biopharma Inc. stockJuly 2025 Opening Moves & Verified Swing Trading Watchlists - mfd.ru
Growth Value: What insider trading reveals about Benitec Biopharma Inc. stockMarket Trend Summary & Smart Money Movement Alerts - mfd.ru
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Yahoo Finance
Hedge funds owners may consider drastic measures as Benitec Biopharma Inc.'s (NASDAQ:BNTC) recent US$60m drop adds to long-term losses - simplywall.st
Wall Street Zen Downgrades Benitec Biopharma (NASDAQ:BNTC) to Sell - MarketBeat
BNTC PE Ratio & Valuation, Is BNTC Overvalued - Intellectia AI
Benitec Biopharma (NASDAQ:BNTC) Announces Quarterly Earnings Results - MarketBeat
Benitec Biopharma Inc. (BNTC) Investor Outlook: Analyst Ratings Signal a Promising 104.58% Upside Potential - DirectorsTalk Interviews
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
Benitec Biopharma Q2 net loss widens - TradingView
BENITEC BIOPHARMA ($BNTC) Releases Q2 2026 Earnings - Quiver Quantitative
Benitec Biopharma Inc. SEC 10-Q Report - TradingView
Is Benitec Biopharma Inc. exposed to political riskSwing Trade & Community Trade Idea Sharing Platform - mfd.ru
Guidance Update: Is Benitec Biopharma Inc forming a breakout patternTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Why (BNTC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Benitec Biopharma (BNTC) Projected to Post Earnings on Friday - MarketBeat
Franklin Resources Inc. Expands Stake in Benitec Biopharma Inc. - GuruFocus
How liquid is Benitec Biopharma Inc stockWeekly Trade Analysis & High Accuracy Swing Trade Signals - baoquankhu1.vn
Benitec Biopharma Limited (NASDAQ:BNTC) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Income Plays: Is Benitec Biopharma Inc stock a good dividend stock2025 Key Lessons & Expert-Curated Trade Recommendations - baoquankhu1.vn
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade - Seeking Alpha
Finanzdaten der Benitec Biopharma Inc-Aktie (BNTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Benitec Biopharma Inc-Aktie (BNTC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 31 '25 |
Buy |
12.83 |
16,497 |
211,736 |
8,807,805 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):